SEARCH

SEARCH BY CITATION

References

  • 1
    Owen CAA, Jr. History of Blood Coagulation. Rochester MN: Mayo Foundation for Medical Education and Research, 2001.
  • 2
    Schmidt A. Zur Blutlehre. Leipzig: FCW Vogel, 1892.
  • 3
    Stedman TL. Stedman's Medical Dictionary, 24th edn. Baltimore MD: Williams & Wilkins, 1982.
  • 4
    Morawitz P. Die chemie der blutgerrinnung. Ergebn Physiol 1905; 4: 307.
  • 5
    Quick AJ. The prothrombin time in haemophilia and in obstructive jaudice. J Biol Chem 1935; 109: 734.
  • 6
    Langdell RD, Wagner RH, Brinkhous KM, , W. Effect of antihemophilic factor on one-stage clotting tests: a presumptive test of hemophilia and a single one-stage anti-hemophilic factor assay procedure. J Lab Clin Med 1953; 41: 763747.
  • 7
    MacFarlane RG. An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier. Nature 2000; 202: 4989.
  • 8
    Davie EW, Ratnoff OD. Waterfall sequence for intrinstic blood clotting. Science 1964; 145: 13102.
  • 9
    Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII. additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 52604.
  • 10
    Gailani D, Broze GJ, Jr. Factor XI activation in a revised model of blood coagulation. Science 1991; 253 (5022): 90912.
  • 11
    Lawson JH, Mann KG. Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. J Biol Chem 1991; 266: 1131727.
  • 12
    Rand MD, Lock JB, Van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996; 88: 343245.
  • 13
    Hemker HC, Beguin S. Phenotyping the clotting system. Thromb Haemost 2000; 84: 74751.
  • 14
    Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze GJ JrTargeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 1996; 88: 15837.
  • 15
    Rosen ED, Chan JC, Idusogie E, Clotman F, Vlasuk G, Luther T, Jalbert LR, Albrecht S, Zhong L, Lissens A, Schoonjans L, Moons L, Collen D, Castellino FJ, Carmeliet P. Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature 1997; 390 (6657): 2904.
  • 16
    Huang ZF, Higuchi D, Lasky N, Broze GJ JrTissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 1997; 90: 94451.
  • 17
    Dewerchin M, Liang Z, Moons L, Carmeliet P, Castellino FJ, Collen D, Rosen ED. Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice. Thromb Haemost 2000; 83: 18590.
  • 18
    Cui J, O'Shea KS, Purkayastha A, Saunders TL, Ginsburg D. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature 1996; 384 (6604): 668.
  • 19
    Sun WY, Witte DP, Degen JL, Colbert MC, Burkart MC, Holmback K, Xiao Q, Bugge TH, Degen SJ. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci USA 1998; 95: 7597602.
  • 20
    Jalbert LR, Rosen ED, Moons L, Chan JC, Carmeliet P, Collen D, Castellino FJ. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest 1998; 102: 14818.
  • 21
    Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH JrTargeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 11921.
  • 22
    Kundu RK, Sangiorgi F, Wu LY, Kurachi K, Anderson WF, Maxson R, Gordon EM. Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice. Blood 1998; 92: 16874.
  • 23
    Suh TT, Holmback K, Jensen NJ, Daugherty CC, Small K, Simon DI, Potter S, Degen JL. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995; 9: 202033.
  • 24
    Poller L. Progress in standardization in anticoagulant control. Hematol Rev 1987; 1: 22541.
  • 25
    Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 23115.
  • 26
    Osterud B. The role of platelets in decrypting monocyte tissue factor. Semin Hematol 2001; 38 (4 Suppl. 12): 25.
  • 27
    Zillmann A, Luther T, Muller I, Kotzsch M, Spannagl M, Kauke T, Oelschlagel U, Zahler S, Engelmann B. Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Commun 2001; 281: 6039.
  • 28
    Santucci RA, Erlich J, Labriola J, Wilson M, Kao KJ, Kickler TS, Spillert C, Mackman N. Measurement of tissue factor activity in whole blood. Thromb Haemost 2000; 83: 44554.
  • 29
    Takahashi H, Satoh N, Wada K, Takakuwa E, Seki Y, Shibata A. Tissue factor in plasma of patients with disseminated intravascular coagulation. Am J Hematol 1994; 46: 3337.
  • 30
    Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 73444.
  • 31
    Van‘t Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen factor VII. implications for the treatment of hemophilia A by factor VIIa. Blood 2000; 95: 13305.
  • 32
    Jesty J, Silverberg SA. Kinetics of the tissue factor-dependent activation of coagulation Factors IX and X in a bovine plasma system. J Biol Chem 1979; 254: 1233745.
  • 33
    Krishnaswamy S, Field KA, Edgington TS, Morrissey JH, Mann KG. Role of the membrane surface in the activation of human coagulation factor X. J Biol Chem 1992; 267: 2611020.
  • 34
    Morrison SA, Jesty J. Tissue factor-dependent activation of tritium-labeled factor IX and factor X in human plasma. Blood 1984; 63: 133847.
  • 35
    Coughlin SR, Vu TK, Hung DT, Wheaton VI. Characterization of a functional thrombin receptor. Issues and opportunities. J Clin Invest 1992; 89: 3515.
  • 36
    Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 1994; 269: 2335766.
  • 37
    Nesheim ME, Pittman DD, Wang JH, Slonosky D, Giles AR, Kaufman RJ. The binding of 35S-labeled recombinant factor VIII to activated and unactivated human platelets. J Biol Chem 1988; 263: 1646770.
  • 38
    Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu Rev Biochem 1988; 57: 91556.
  • 39
    Foster WB, Nesheim ME, Mann KG. The factor Xa-catalyzed activation of factor V. J Biol Chem 1983; 258: 139707.
  • 40
    Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991; 266: 73538.
  • 41
    Broze GJ JrTissue-factor inhibitor is also a factor Xa inhibitor. Clin Res 1987; 35: 597.
  • 42
    Baugh RJ, Broze GJ Jr, Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem 1998; 273: 437886.
  • 43
    Olson ST, Bjork I, Shore JD. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Meth Enzymol 1993; 222: 52559.
  • 44
    Shigematsu Y, Miyata T, Higashi S, Miki T, Sadler JE, Iwanaga S. Expression of human soluble tissue factor in yeast and enzymatic properties of its complex with factor VIIa. J Biol Chem 1992; 267: 2132937.
  • 45
    Lawson JH, Butenas S, Ribarik N, Mann KG. Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. J Biol Chem 1993; 268: 76770.
  • 46
    Church FC, Pratt CW, Hoffman M. Leukocyte chemoattractant peptides from the serpin heparin cofactor II. J Biol Chem 1991; 266: 7049.
  • 47
    Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 21629.
  • 48
    Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 47436.
  • 49
    Fay PJ, Smudzin TM, Walker FJ. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem 1991; 266: 2013945.
  • 50
    Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 3186980.
  • 51
    Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem 2002; 277: 1832233.
  • 52
    Butenas S, Van’t Veer C, Mann KG. ‘Normal’ thrombin generation. Blood 1999; 94: 216978.
  • 53
    Van‘t Veer C, Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin- III, and heparin cofactor-II. J Biol Chem 1997; 272: 436777.
  • 54
    Jones KC, Mann KG. A model for the tissue factor pathway to thrombin. II. A mathematical simulation. J Biol Chem 1994; 269: 2336773[published erratum appears in J Biol Chem 1995; 270: 9026].
  • 55
    Hockin MF, Cawthern KM, Kalafatis M, Mann KG. A model describing the inactivation of factor Va by APC. Bond cleavage, fragment dissociation, and product inhibition. Biochemistry 1999; 38: 691834.
  • 56
    Cawthern KM, Van‘t Veer C, Lock JB, DiLorenzo ME, Branda RF, Mann KG. Blood coagulation in hemophilia A and hemophilia C. Blood 1998; 91: 458192.
  • 57
    Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100: 14852.
  • 58
    Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, factor XIII and by enhancing factor Va inactivation. Circulation 2001; 103: 224853.
  • 59
    Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Aspirin and cardioprotective effects of the Val34Leu polymorphism of factor XIII. Circulation; 104: II12[Abstract].
  • 60
    Undas A, Wojciech JS, Brummel K, Musial J, Mann K, Szczeklik A. Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Circulation 2003; 173: 1720.
  • 61
    Butenas S, Branda RF, Van’t Veer C, Cawthern KM, Mann KG. Platelets and phospholipids in tissue factor-initiated thrombin generation. Thromb Haemost 2001; 86: 6607.
  • 62
    Brummel KE, Butenas S, Mann KG. An integrated study of fibrinogen during blood coagulation. J Biol Chem 1999; 274: 2286270.
  • 63
    Van‘t Veer C, Golden NJ, Kalafatis M, Mann KG. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor. J Biol Chem 1997; 272: 798394.
  • 64
    Mann KG, Kalafatis M. Factor V: a combination of Dr. Jekyll and Mr. Hyde. Blood 2003; 101: 2030.
  • 65
    Walsh PN. Factor XI. In: ClomanRW, HirshJ, MarderVJ, ClowesAW, GeorgeJN, eds. Hemostasis and Thrombosis: Basic Principles & Clinical Practice. Philadelphia: Lippincott Williams & Wilkins, 2001.
  • 66
    Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. Blood coagulation at the site of microvascular injury: effects of low-dose aspirin. Blood 2001; 98: 242331.
  • 67
    Butenas S, Cawthern KM, Van’t Veer C, DiLorenzo ME, Lock JB, Mann KG. Antiplatelet agents in tissue factor-induced blood coagulation. Blood 2001; 97: 231422.
  • 68
    Brummel KE, Paradis SG, Branda RF, Mann KG. Oral anticoagulation thresholds. Circulation 2001; 104: 23117.
  • 69
    Van‘t Veer C, Kalafatis M, Bertina RM, Simioni P, Mann KG. Increased tissue factor-initiated prothrombin activation as a result of the Arg506[RIGHTWARDS ARROW]Gln mutation in factor V LEIDEN. J Biol Chem 1997; 272: 207219.
  • 70
    Eitzman DT, Westrick RJ, Bi X, Manning SL, Wilkinson JE, Broze GJ, Ginsburg D. Lethal perinatal thrombosis in mice resulting from the interaction of tissue factor pathway inhibitor deficiency and factor V Leiden. Circulation 2002; 105: 213942.